Molecular
BCR-ABL1
Non-Standard p230 – Effective December
11th, 2023, this test will be updated to be a Qualitative
assay.
- Results will be reported
out as Detected or Not Detected.
- The analytical sensitivity
of the test is 0.1%.
- The result of this test
should not be used as the sole criterion for confirming a diagnosis of
CML. Correlation with cytogenetic, FISH, and hematologic findings is
highly recommended.
- Monitoring of positive
p230 cases can be achieved using this test in combination with the BCR/ABL1/ASS1
t(9;22) FISH assay.
There’ll be no changes in
CPT codes and pricing. This update applies only to cases accessioned from
Monday, December 11th.
Reminder! The following comprehensive genomic profiles for hematologic
malignancies are now available! These assays can provide key diagnostic,
therapeutic, and clinical trial information. They can also aid in risk
stratification, prognostic prediction, and support clinical research.
- Neo
Comprehensive™ – Myeloid Disorders analyzes 164
pertinent genes in myeloid neoplasms.
- DNA sequencing: SNVs/InDels in 126 genes and copy number
variants (CNVs) in 17 genes
- RNA sequencing: known and novel fusions in 40 genes
- Neo
Comprehensive™ – Heme Cancers analyzes 433 relevant
genes in hematologic cancers.
- DNA sequencing: SNVs/InDels in 302 genes and CNVs in 23
genes
- RNA sequencing: known and novel fusions in 184 genes
New Test
The Early-stage NSCLC
Panel analyzes 4 actionable and informative early-stage NSCLC biomarkers,
EGFR (PCR), ALK (FISH), ROS1 (FISH), PD-L1 22C3 (IHC), relevant for
diagnostic evaluation and therapy-selection. This panel is aligned with
emerging published clinical trial evidence and the latest clinical testing
guidelines, associated with approved targeted therapies. For more info,
please contact your local NeoGenomics representative or visit the Early-stage
NSCLC webpage.
Special Announcement
NeoGenomics
will be at the 65th ASH Annual Meeting and Exposition
We at NeoGenomics are so
excited to be a part of the 65th ASH Annual Meeting and Exposition. We are
the market leader in Oncology Diagnostics for over 20 years. With over 1.7 million
cancer-related tests per year, and an extensive range of over 500 clinical
cancer tests available, we are your trusted partner in
patient care. We will be showcasing our cutting-edge heme based solutions
including: Neo Comprehensive™ - Heme Cancers, Neo Comprehensive™ - Myeloid
Disorders and COMPASS® Hematopathology Services.
You will find us at Booth #851. Visit our webpage
to schedule a meeting with a NeoGenomics representative to learn more about
our heme assays.
|